LexaGene is a biotechnology company developing automated and sensitive instrumentation for rapid pathogen detection.
Our breakthrough technology will transform how pathogens are detected and deliver results in about an hour.
29 May 2018 – LexaGene has entered into an agreement with the Stanford University School of Medicine to incorporate cancer sequencing technology into a new product.
Innovation in the Making
Imagine a new way of testing on site for multiple pathogens that uses customized genetic screening, doesn’t require a skilled technician,
and returns results in just one hour. See what’s new with LexaGene and how we are changing the future of pathogen detection.
LexaGene featured on Fox Biz TV
LexaGene was featured on an episode of Innovations with Ed Begley Jr. which aired on Fox Business Network in fall 2017. Learn more about LexaGene by watching the segment.
LexaGene Company Presentation
We are commercializing the first ‘open-access’ instrument for pathogen detection, allowing users an on-site instrument to target any gene sequence of interest, and return results in about an hour.
E.Coli update: Note from CEO
The widespread romaine lettuce E. coli outbreak has sickened 149 people across 29 states and killed one person, according to the latest numbers from the Centers for Disease Control. LexaGene’s CEO addresses preventing future foodborne illness.